Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BHP settles Australian Samarco shareholder class action

(Sharecast News) - Mining giant BHP said on Tuesday that it has reached an agreement to settle the Australian Samarco shareholder class action, subject to approval by the Federal Court of Australia. Under the terms of the settlement agreement, BHP has agreed to pay the applicants AUD $110m (£53.56m), inclusive of interests and costs, with no admission of liability. BHP expects to recover the majority of the settlement amount from its insurers.

BHP said the Australian shareholder class action was brought on behalf of shareholders who acquired BHP shares before the Fundão Dam failure and was filed in the Federal Court of Australia in 2018.

The Fundão Dam was owned and operated by Samarco Mineração, a non-operated joint venture between BHP Billiton Brasil, a subsidiary of BHP Group and Vale, each of which holds a 50% stake in Samarco.

The settlement comes almost ten years after the Samarco dam disaster, which occurred on 5 November 2015, when the Fundão tailings dam at the Germano iron ore mine suffered a catastrophic failure, resulting in flooding that devastated the downstream villages of Bento Rodrigues and Paracatu de Baixo, killing 19 people. The extent of the damage caused by the tailings dam collapse was the largest ever recorded, with pollutants spread along 668 kilometres of watercourses.

As of 0805 BST, BHP shares were down 0.30% at 1,992.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.